Inventiva reported its full-year financial results for 2024, with cash and cash equivalents at €96.6 million as of December 31, 2024, a significant increase from €26.9 million at the end of 2023. The net cash used in operating activities for 2024 was (€85.9) million, an increase of 5.3% from 2023.
Research and development expenses for 2024 amounted to (€90.9) million, a 17% decrease from €110.0 million in 2023, primarily due to a temporary pause in the NATiV3 trial and completion of the LEGEND trial. The company's net loss for the full year 2024 was (€184.2) million, compared to (€110.4) million in 2023, largely driven by a (€86.0) million net financial loss due to non-cash IFRS treatment of derivative instruments.
Revenues for 2024 were €9.2 million, mainly from a $10 million milestone payment from CTTQ. Inventiva reiterated its strategic pipeline prioritization plan, focusing exclusively on lanifibranor, which includes discontinuing other preclinical programs and a 50% workforce reduction expected in Q2 2025. The company anticipates its cash runway will extend to the end of Q3 2026, contingent on receiving €116 million from the second tranche of structured financing and another $10 million CTTQ milestone in Q2 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.